The OVCAR-3 cell line originates from human ovarian adenocarcinoma, a subtype of ovarian cancer known for its epithelial cell origin. Ovarian cancer, often termed the “silent killer”, is notorious for its insidious onset and frequent late-stage diagnosis. The OVCAR-3 cell line, characterized by specific genetic mutations and molecular markers, provides an essential platform for studying the intricacies, progression, and potential therapeutic challenges associated with ovarian adenocarcinoma. Representing a genetic profile and molecular features commonly found in ovarian cancer patients, OVCAR-3 plays a pivotal role in preclinical investigations. The in vitro and in vivo behaviors of OVCAR-3 shed light on tumor growth dynamics, invasive capabilities, and therapeutic responses of ovarian tumors. Researchers extensively utilize the OVCAR-3 model to decode the molecular and cellular dynamics of ovarian cancer, evaluate the efficacy of novel therapeutic interventions, and to understand potential resistance mechanisms to standard therapies.

Model Details

Cancer Location: Ovarian
Cancer Type: Ovarian Cancer
Model Name: OVCAR-3
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Olaparib, Niraprib, Carboplatin, Paclitaxel)

OVCAR-3 Growth curves


Growth of subcutaneous OVCAR-3 in Nu/Nu mice (n=8)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.